Pharma Focus Europe

Acino Successfully Finalizes the Acquisition of M8 Pharmaceuticals, Significantly Expanding Its Presence and Capabilities in Latin America

Tuesday, December 05, 2023

Acino, a Swiss pharmaceutical company based in Zurich, has recently finalized the acquisition of M8 Pharmaceuticals, a rapidly growing specialty biopharmaceutical firm headquartered in Mexico City. M8 focuses on licensing, marketing, and distributing innovative medicines in Mexico and Brazil. This strategic move provides Acino access to the two largest pharmaceutical markets in Latin America, expanding its geographic presence and strengthening its position in the region. The integration of M8's portfolio, pipeline, and operations with Acino is currently in progress, with both companies continuing their day-to-day activities.

Formerly part of the Montreux Growth Partners portfolio, M8 brings a portfolio of well-established brands and innovative products, a top-tier deal-making platform, and a stellar reputation among its partners. M8 has also developed an extensive pipeline covering key therapeutic areas such as CNS, cardiometabolism, respiratory, gastroenterology, oncology and hematology, and rare diseases.

Andrew Bird, Interim CEO at Acino, expressed his enthusiasm about the transformative impact of the deal, highlighting the expansion of Acino's reach and the opportunity to diversify the business across geographies, partnerships, product portfolios, and therapeutic areas. He welcomed the nearly 300 new colleagues from M8 into the Acino family, emphasizing the alignment of company cultures and dedication to excellence.

Joel Barlan, CEO at M8, sees this as an exciting new chapter for both companies. He looks forward to collaborating with Acino to grow the combined business and continue delivering proven and innovative treatments to patients and caregivers in Latin America and other emerging markets.

Banco J.P. Morgan S.A. served as the exclusive financial advisor, with Goodwin Procter LLP, Creel and Demarest Advogados as legal advisors, and PWC as the exclusive accounting and tax advisor to Acino. Stifel, Cooley LLP, and Credit Suisse, a UBS Group Company, acted as advisors to M8.

 

Source: globenewswire.com

magazine-slider-img
Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024
cytiva